Global News and Digital Insights
for the Healthcare Industry

Oncopeptides gains CHMP’s nod of approval for multiple myeloma drug

While Oncopeptides was taken off the market in the US after the FDA showed concerns, it has received a recommendation by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP). The drug, named as Pepaxto in Europe, has now been approved for full marketing. In February 2021, the FDA approved it as an infused treatment. However, in October, it was banned due to some concerns. The firm, however, did not give up and has finally gained the nod they sought.

Read More from FiercePharma

Share on facebook
Share on twitter
Share on linkedin